Novartis AG (ADR) 

(Public, NYSE:NVS)   Watch this stock   
Find more results forNVS
Apr 19, 2010
Q1 2010 AG Earnings Release Add to calendar
Feb 25, 2010
NOVARTIS AG Annual General Meeting Add to calendar
Jan 26, 2010
Full Year 2009 AG Earnings Conference Call
Jan 25, 2010
Full Year 2009 AG Earnings Release
Jan 4, 2010
Alcon, a global leader in eye care, and proposes merger for full ownership Conference Call - Webcast
Nov 26, 2009
AG Foundation Symposium in Basel
More events from AOL Finance »    

Key stats and ratios

Q4 (Dec '09) 2009
Net profit margin 17.67% 18.74%
Operating margin 20.06% 22.09%
EBITD margin - 27.19%
Return on average assets 10.01% 9.73%
Return on average equity 16.70% 15.60%
Employees 99,834 -

Address

Lichtstrasse 35
Basel, 4022
Switzerland

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

Novartis AG (ADR) discussed on blogs

Health Care Renewal: Green Ketchup for Novartis? - Roy M. Poses MD - Health Care Renewal - 36 minutes ago
Cancer News & Information » UK Body Says Novartis, Bristol Cancer ... - cancer - Google News - Cancer News & Information - 6 hours ago
Positive Results On Amgen Drug | Daily Markets - Zacks Investment Research - Daily Markets - 6 hours ago

Novartis AG (ADR) discussions

  View all discussions »

Description

Novartis AG is a Switzerland-based holding that, through its subsidiaries, is engaged in the research, development, manufacture and marketing of healthcare products. The Company’s healthcare solutions portfolio includes medicines, preventive vaccines and diagnostic tools, generic pharmaceuticals and consumer health products. Its businesses are divided on a worldwide basis into four operating divisions: Pharmaceuticals, which comprises brand-name patented pharmaceuticals; Vaccines and Diagnostics, which focuses on human vaccines and blood-testing diagnostics; Sandoz, which consists of generic pharmaceuticals, and Consumer Health, which includes over-the-counter medicines, animal health medicines, and contact lenses and lens-care products. It operates in approximately 140 countries. On June 8, 2009, the Company acquired additional 26% interest in its Indian subsidiary, Novartis India Ltd.

Officers and directors

Daniel L. Vasella M.D.
Chairman of the Board
Age: 57
Bio & Compensation - Reuters
Joseph Jimenez
Chief Executive Officer
Age: 50
Bio & Compensation - Reuters
Jonathan R. Symonds
Chief Financial Officer
Age: 50
Bio & Compensation - Reuters
David R. Epstein
Head of the Pharmaceuticals Division
Bio & Compensation - Reuters
Jeffrey George
Head of Generics Division
Age: 36
Bio & Compensation - Reuters
George Gunn
Head of Consumer Health Division
Age: 59
Bio & Compensation - Reuters
Andrin Oswald M.D.
Head of Vaccines and Diagnostics Division
Age: 38
Bio & Compensation - Reuters
Thomas Werlen Ph.D.
General Counsel
Age: 44
Bio & Compensation - Reuters
Juergen Brokatzky-Geiger Ph.D.
Global Head Human Resources
Age: 58
Bio & Compensation - Reuters
Mark C. Fishman M.D.
Global Head of Novartis Institute for BioMedical Research (NIBR)
Age: 58
Bio & Compensation - Reuters